General
Preferred name
didanosine
Synonyms
ddI ()
2',3'-Dideoxyinosine ()
NSC-612049 ()
(-)-didanosine ()
Didanosina ()
Didanosinum ()
BMY-40900 ()
Videx Ec ()
Didanosine system suitability mixture ()
Dideoxyinosine (DDI) ()
Videx ()
P&D ID
PD003179
CAS
69655-05-6
Tags
available
prodrug
drug
Approved by
FDA
First approval
1991
Drug indication
HIV infection
Human immunodeficiency virus infection
Drug Status
approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS
Didanosine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Didanosine is a hypoxanthine attached to the sugar ring, unlike other nucleoside analogues. Didanosine is phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit the HIV reverse transcriptase enzyme competitively and act as a chain terminator of DNA synthesis. Didanosine is effective against HIV, and usually used in combination with other antiviral therapy. Switching from long term AZT treatment to didanosine has been shown to be beneficial. Didanosine has weak acid stability and therefore, it is often combined with an antacid.
DESCRIPTION
Didanosine is an antiretroviral drug.
(GtoPdb)
DESCRIPTION
Didanosine (2',3'-Dideoxyinosine; ddI) is a a potent and orally active dideoxynucleoside analogue, and also is a potent nucleoside reverse transcriptase inhibitor. Didanosine shows antiretroviral activity for HIV[1][2][3].
PRICE
29
DESCRIPTION
Didanosine (ddI) is a nucleoside reverse transcriptase inhibitor analog of adenosine (IC50: 0.49 ??M).
DESCRIPTION
Didanosine is a nucleoside reverse transcriptase inhibitor with activity against HIV-1. Didanosine is a hypoxanthine attached to the sugar ring, unlike other nucleoside analogues.
(Enamine Bioactive Compounds)
DESCRIPTION
Didanosine (ddI) is a nucleoside reverse transcriptase inhibitor analog of adenosine (IC50: 0.49 μM).
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
3
Organisms
2
Compound Sets
27
AdooQ Bioactive Compound Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine Bioactive Compounds
Enamine BioReference Compounds
Guide to Pharmacology
MedChem Express Bioactive Compound Library
NIH Clinical Collections (NCC)
NPC Screening Collection
Pandemic Response Box
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
60
Molecular Weight
236.09
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
2
Rotatable Bonds
2
Ring Count
3
Aromatic Ring Count
2
cLogP
0.2
TPSA
93.29
Fraction CSP3
0.5
Chiral centers
2.0
Largest ring
6.0
QED
0.77
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
HIV
Reverse Transcriptase
PNP
Indication
human immunodeficiency virus (HIV-1)
MOA
nucleoside reverse transcriptase inhibitor
Therapeutic Class
Anti-HIV Agents
Pathway
Microbiology/virology
Proteases/Proteasome
Anti-infection
Source data
